The U.S. Food and Drug Administration issued a safe‑to‑proceed letter on April 30, 2026, and the company announced the decision on May 1, 2026. The letter allows Revolution Medicines to launch an expanded‑access treatment protocol for daraxonrasib, giving patients with previously treated metastatic pancreatic cancer a chance to receive the drug before formal approval is obtained.
Daraxonrasib is a RAS(ON) inhibitor that targets the most common driver mutation in pancreatic cancer. In the Phase 3 RASolute 302 trial, announced on April 13, 2026, the drug produced a median overall survival of 13.2 months versus 6.7 months for standard chemotherapy, a nearly two‑fold improvement that underpins the FDA’s expedited action.
The early‑access authorization follows the drug’s breakthrough‑therapy and orphan‑drug designations and its inclusion in the FDA Commissioner’s National Priority Voucher pilot program, all of which accelerate review and potential approval. These designations signal the agency’s confidence in the drug’s clinical benefit and the urgency of addressing a disease with limited options.
Pancreatic cancer remains one of the most lethal malignancies, with RAS mutations present in nearly all cases and survival rates below 10 % at five years. Daraxonrasib’s mechanism of action directly inhibits the mutant RAS protein, offering a targeted approach that could transform the therapeutic landscape for this patient population.
Revolution Medicines has stated it is “moving as quickly as possible to ensure safe and equitable access to daraxonrasib for eligible patients in the United States.” The expanded‑access protocol will allow patients to receive the drug before formal approval, potentially positioning daraxonrasib as a new standard of care if subsequent data confirm its efficacy and safety.
The company’s broader RAS(ON) platform is being advanced in multiple Phase 3 trials, including RASolute 303 (first‑line metastatic disease) and RASolute 304 (adjuvant setting). These efforts underscore Revolution Medicines’ commitment to addressing RAS‑driven cancers across disease sites.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.